Last reviewed · How we verify
Human-derived stromal cells
At a glance
| Generic name | Human-derived stromal cells |
|---|---|
| Sponsor | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD (NA)
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease (PHASE1)
- Tolerance by Engaging Antigen During Cellular Homeostasis (PHASE1)
- Extracellular Vesicles for the Treatment of Syringomyelia (PHASE1)
- Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy (PHASE2)
- Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis (PHASE1, PHASE2)
- A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: